McKesson Corporation stock (US58155Q1031): Norges Bank emerges as major new shareholder

McKesson Corporation shares on the New York Stock Exchange traded in the mid-USD 740 range this week, as new regulatory filings in the United States showed that Norges Bank established a sizeable position in the healthcare distributor, underlining ongoing institutional interest in one of the largest drug wholesalers in the United States, according to MarketBeat on 05/30/2026 and a recent 13F filing with the SEC.

MarketBeat reported that Norges Bank acquired 2,012,870 McKesson shares in the fourth quarter, making the Norwegian central bank one of the larger institutional holders of the NYSE-listed stock based on the most recent public data as of 05/30/2026, while a separate filing showed Fideuram Asset Management Ireland DAC also buying 1,417 shares in the company during the same period.

The stock traded at USD 741.47 during Friday's session, according to MarketBeat as of 05/30/2026, placing the current price below the consensus analyst target price of USD 968.87 that MarketBeat calculated from recent research reports, and indicating that the shares are still changing hands at a discount to where the analyst community collectively models fair value based on their earnings projections.

In the United States home market, McKesson is listed on the NYSE under the ticker MCK and is part of the large-cap healthcare segment rather than a main equity index, while German investors can access the stock via secondary trading on venues such as Tradegate or Frankfurt where prices are quoted in euro that typically track the US listing adjusted for exchange rates.

MarketBeat also noted that McKesson has communicated guidance for fiscal year 2027 earnings per share in a range of USD 43.80 to USD 44.60, while the consensus forecast compiled by the platform sits at USD 44.29 for the current year as of 05/30/2026, suggesting that analysts expect the company to deliver mid-single-digit percentage EPS growth supported by its core distribution and services businesses.

The latest data from MarketBeat as of 05/30/2026 show that equities research analysts have an average "Moderate Buy" rating on McKesson, with the USD 968.87 consensus price target based on multiple published notes from US and international banks that follow the company as part of their healthcare and distribution coverage.

According to trading information published by Robinhood and other market data providers on 05/30/2026, McKesson carries a market capitalization around USD 89 billion at recent prices, and the stock has shown solid long-term appreciation even if returns over the last one to three months have been more muted compared with earlier periods of outperformance.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

McKesson Corporation: core business model

McKesson Corporation primarily focuses on large-scale distribution of pharmaceuticals and medical products for pharmacies, hospitals and healthcare providers, complemented by technology-enabled services that support supply chains, specialty care and medication management.

Insider activity and ownership structure

While there were no high-profile director dealings disclosed for late May 2026, the ownership profile of McKesson has been reshaped at the margin by institutional investors, as Norges Bank's new position of 2,012,870 shares reported in its latest 13F filing for the fourth quarter demonstrates a strong vote of confidence from a major sovereign wealth-related institution, according to MarketBeat on 05/30/2026.

The separate disclosure that Fideuram Asset Management Ireland DAC acquired 1,417 McKesson shares in the same period reinforces the picture of continued, if incremental, institutional buying, and together these holdings add to an already high proportion of the free float held by asset managers and long-term institutional investors tracking US healthcare and distribution names.

Conclusion

Recent filings showing Norges Bank's multi-million-share position and Fideuram Asset Management Ireland's additional purchase have put McKesson Corporation's shareholder structure back in focus, supporting the narrative of sustained institutional engagement with the NYSE-listed healthcare distributor.

Combined with guidance that implies earnings per share in the mid-USD 40s for fiscal year 2027 and a consensus analyst price target well above the current mid-USD 740 trading level, these developments provide investors with fresh data points when weighing McKesson's risk-reward profile within the broader US healthcare and distribution landscape.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.